公开(公告)号：US11591595B2

公开(公告)日：2023-02-28

申请号：US16986770

申请日：2020-08-06

Applicant: Biogen MA Inc.

Inventor： Holly Kordasiewicz ,  Eric E. Swayze ,  Susan M. Freier ,  Huynh-Hoa Bui

IPC: C12N15/113 ,  A61K31/711 ,  C07H21/02

Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.

公开(公告)号：US11572356B2

公开(公告)日：2023-02-07

申请号：US17004411

申请日：2020-08-27

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Timothy Raymond Chan ,  Lihong Sun ,  Lei Zhang ,  Gnanasambandam Kumaravel ,  Joseph P. Lyssikatos ,  Kevin Koch ,  Hua Miao

IPC: C07D403/12 ,  C07D417/14 ,  C07D495/04 ,  C07D409/14 ,  C07D401/14 ,  C07D513/04 ,  C07D413/14 ,  A61K31/506 ,  C07D239/30 ,  C07F5/02 ,  C07D417/12 ,  C07D487/04

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20230002361A1

公开(公告)日：2023-01-05

申请号：US17623182

申请日：2020-06-24

Applicant: BIOGEN MA INC.

Inventor： Emily Anne Peterson ,  Ryan Evans ,  Fang Gao ,  Philippe Bolduc ,  Magnus Pfaffenbach ,  Zhili Xin

IPC: C07D405/14 ,  C07D471/04 ,  C07D401/12 ,  C07D487/04 ,  C07D519/00

Abstract: This invention relates to 2H-indazole Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US20220397571A1

公开(公告)日：2022-12-15

申请号：US17705092

申请日：2022-03-25

Applicant: Biogen MA Inc.

Inventor： Leonid GORELIK ,  Kenneth J. SIMON ,  Meena SUBRAMANYAM ,  Mia Marie RUSHE

IPC: G01N33/543

Abstract: The invention relates to methods and reagents for analyzing samples for the presence of JC virus antibodies.

公开(公告)号：US20220375083A1

公开(公告)日：2022-11-24

申请号：US17805505

申请日：2022-06-06

Applicant: BIOGEN MA INC.

Inventor： Elizabeth FISHER

IPC: G06T7/00 ,  G06T7/62 ,  A61B5/00 ,  A61B5/055

Abstract: Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and third brain volume (BV) values at the first time point based on two or more images from the first set of medical images and second and fourth BV values at the second time point based on two or more images from the second set of medical images. A mathematical weight may be applied to at least one of the first, second, third, or fourth BV values. The first and third BV values may be averaged, and the second and fourth BV values may be averaged to determine overall BV values at the first and second time points, respectively.

公开(公告)号：US20220357338A1

公开(公告)日：2022-11-10

申请号：US17700242

申请日：2022-03-21

Applicant: Biogen MA Inc.

Inventor： Tatiana Plavina ,  Paula S. Hochman ,  Michaela Lerner

IPC: G01N33/68 ,  G01N33/558 ,  G01N33/566 ,  G01N33/94

Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

公开(公告)号：US20220195052A1

公开(公告)日：2022-06-23

申请号：US17599716

申请日：2020-04-08

Applicant: Biogen MA Inc.

Inventor： Christilyn Graff ,  Christina Palmer ,  Brett Blakeley ,  Tracey Mullen ,  Agnes Gardet

IPC: C07K16/28

Abstract: Anti-integrin antibodies are disclosed. Also disclosed are methods of using the antibodies to treat or prevent disorders such as fibrotic diseases, cancer, ophthalmology disorders, and NAFLD. Further disclosed are methods of selecting an antibody that specifically binds to αvβ{umlaut over (í)}, or that binds to αvβ{umlaut over (í)} and αvβó, or that binds to one or more members of the RGD sub-family of integrins.

公开(公告)号：US20220177426A1

公开(公告)日：2022-06-09

申请号：US17602585

申请日：2020-04-09

Applicant: Biogen MA Inc.

Inventor： Donald G. Walker ,  Dino Alberico ,  Joshua Clayton ,  Chandrasekhar Navuluri

IPC: C07D207/16 ,  C07D207/28 ,  C07D263/18 ,  C07C269/06 ,  C07C51/60

Abstract: Disclosed are processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and intermediates for use in said processes along with processes for preparing said intermediates.

公开(公告)号：US11292845B2

公开(公告)日：2022-04-05

申请号：US16357179

申请日：2019-03-18

Applicant: BIOGEN MA INC.

Inventor： Ivan Lieberburg

IPC: A61K39/395 ,  C07K16/28 ,  G01N33/68 ,  A61K38/03 ,  A61K38/21 ,  A61K45/06 ,  A61K49/00 ,  A61K39/00

Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

公开(公告)号：US20220098150A1

公开(公告)日：2022-03-31

申请号：US17322382

申请日：2021-05-17

Applicant: Biogen MA Inc.

Inventor： Nishanth Gopinathan ,  Erwin Irdam ,  William Kiesman ,  Daw-long A. Kwok ,  Yiqing Lin ,  Frederick Osei-Yeboah ,  Matthew Peterson ,  Kenny Tran ,  Kalyan Vasudevan

IPC: C07D207/16

Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[2-fluorophenyl)methyl]oxy}phenyl-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.